Elevation Oncology Inc [ELEV] stock is trading at $0.23, down -5.13%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ELEV shares have lost -5.86% over the last week, with a monthly amount drifted -50.48%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Elevation Oncology Inc [NASDAQ: ELEV] stock has seen the most recent analyst activity on March 24, 2025, when Stephens downgraded its rating to a Equal-Weight and also revised its price target to $1 from $5. Previously, Piper Sandler downgraded its rating to Neutral on March 21, 2025, and kept the price target unchanged to $0.70. On March 21, 2025, downgrade downgraded it’s rating to Market Perform but maintained its price target of $1 on the stock. Citizens JMP downgraded its rating to a Mkt Perform. William Blair initiated its recommendation with a Outperform. Piper Sandler started tracking with a Overweight rating for this stock on May 31, 2024, and assigned it a price target of $10. In a note dated May 14, 2024, Stephens initiated an Overweight rating and provided a target price of $8 on this stock.
Elevation Oncology Inc [ELEV] stock has fluctuated between $0.23 and $4.98 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Elevation Oncology Inc [NASDAQ: ELEV] shares were valued at $0.23 at the most recent close of the market. An investor can expect a potential return of 3813.04% based on the average ELEV price forecast.
Analyzing the ELEV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.62 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2274 points at the first support level, and at 0.2218 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2440, and for the 2nd resistance point, it is at 0.2550.
Ratios To Look Out For
For context, Elevation Oncology Inc’s Current Ratio is 21.21. In addition, the Quick Ratio stands at 21.21 and the Cash Ratio stands at 11.07.
